Cdk-inhibition as putative new glioblastoma therapy

Glioblastoma multiforme is characterized by a high invasive and infiltrative tumor growth. Roscovitine, a cyclin dependent kinase (cdk)-inhibitor, is already used in clinical trials against cancer of different origin. It not only inhibits cell cycle dependent cdks (2, 7, 8 and 9) but also cdk5, which plays a role in cell migration. This dual activity makes roscovitine an interesting putative candidate for glioblastoma therapy. Thus, the influence of roscovitine on human glioma cell lines was evaluated in vitro. Treated cells showed concentration-dependent significant proliferation inhibition, reduced viability a…